MK-677 (Ibutamoren) and Pregabalin Interaction: What You Need to Know

Why This Combination Raises Concern

MK-677 (ibutamoren) is an oral growth hormone secretagogue that mimics ghrelin signaling to boost GH and IGF-1 levels. Pregabalin is a gabapentinoid anticonvulsant prescribed for neuropathic pain, fibromyalgia, generalized anxiety disorder (in some countries), and partial-onset seizures. Patients using MK-677 for investigational or off-label purposes who also take pregabalin face overlapping pharmacodynamic risks rather than a classic drug-drug metabolic clash.

No Major Pharmacokinetic Conflict

Pregabalin undergoes negligible hepatic metabolism. Approximately 98% of the drug is excreted unchanged in urine, and it does not inhibit or induce any CYP450 enzymes according to the FDA-approved Lyrica prescribing information. MK-677 is metabolized primarily via CYP3A4, but because pregabalin bypasses hepatic pathways entirely, no competitive enzyme inhibition occurs between the two compounds. Plasma levels of each agent are unlikely to change because of the other.

The Real Risk Is Pharmacodynamic

The concern is additive side effects. Both substances independently cause sedation, peripheral edema, and changes in glucose homeostasis. When layered, these effects may intensify beyond what either drug produces alone. A 2008 randomized trial by Nass et al. (N=65, aged 60-81) published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 at 25 mg/day increased fasting glucose by an average of 0.3 mmol/L (approximately 5.4 mg/dL) over 12 months, with some participants developing impaired fasting glucose. Pregabalin, separately, is associated with dose-dependent weight gain averaging 1.6 kg at 12 weeks in fibromyalgia trials, which can further stress insulin sensitivity.

Sedation and CNS Depression: The Primary Safety Signal

Both MK-677 and pregabalin affect central nervous system function through distinct mechanisms. Together, their sedative burden adds up in ways that matter for daily functioning and safety.

How Each Drug Causes Drowsiness

MK-677 activates ghrelin receptors (GHSR1a) in the hypothalamus. Ghrelin signaling promotes slow-wave sleep, and users commonly report deeper sleep onset and vivid dreams. A study by Copinschi et al. Found that MK-677 increased stage IV sleep duration by approximately 50% and REM sleep by 20% in young healthy males. While this is often considered a benefit, it reflects genuine CNS modulation.

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. The FDA label reports somnolence in 15-25% of patients at therapeutic doses (150-600 mg/day) and dizziness in 10-38%. These are the two most common adverse events in pregabalin registration trials across indications.

Combined Sedation in Practice

No published clinical trial has directly tested concurrent use. Based on pharmacodynamic extrapolation, a patient taking both agents should expect greater next-morning grogginess, slower reaction times, and increased fall risk, particularly during the first two weeks. The Endocrine Society's clinical practice guidelines on GH use in adults emphasize that concomitant CNS-active medications require dose titration awareness to avoid compounding sedation-related risks.

Practical advice: take MK-677 at bedtime (capitalizing on its sleep-promoting effect) and take the largest pregabalin dose at bedtime as well, so that peak sedation of both drugs overlaps during intended sleep rather than daytime hours.

Peripheral Edema: An Additive Fluid-Retention Problem

Both MK-677 and pregabalin cause fluid retention through different pathways, and combining them may produce clinically meaningful edema in patients who tolerate each drug alone.

Mechanism of Edema With MK-677

Growth hormone promotes sodium and water retention via direct renal tubular effects and by increasing IGF-1, which stimulates the renin-angiotensin-aldosterone system. In the Nass et al. 2008 trial, peripheral edema occurred in approximately 15% of MK-677-treated older adults versus 4% on placebo during 12-month treatment.

Mechanism of Edema With Pregabalin

Pregabalin-associated edema appears related to calcium channel modulation in vascular smooth muscle, causing arteriolar vasodilation and increased capillary hydrostatic pressure. The FDA label reports peripheral edema in 6% of pregabalin-treated patients across pooled analyses, with higher rates (up to 16%) at doses of 600 mg/day. Concomitant thiazolidinedione use further amplifies this risk.

Clinical Significance

A patient with baseline mild ankle swelling on pregabalin 300 mg/day who adds MK-677 at 25 mg/day could develop enough edema to require dose reduction or diuretic therapy. Patients with congestive heart failure (NYHA class III-IV) should avoid this combination entirely. The Murphy et al. 2001 trial of MK-677 in heart failure patients (N=309) was terminated early because MK-677-treated patients experienced significantly higher rates of CHF exacerbation compared to placebo.

Metabolic Effects: Glucose, Insulin, and Weight

The metabolic profiles of MK-677 and pregabalin overlap in a clinically relevant way. Both contribute to weight gain and can worsen glycemic control through distinct mechanisms.

MK-677 and Insulin Resistance

MK-677 increases GH secretion, and GH is a counter-regulatory hormone that opposes insulin action. In the Nass et al. Study, fasting insulin levels rose by approximately 1.4 mU/L at 6 months, and two participants (out of 32 on active drug) developed new-onset type 2 diabetes during the 12-month trial. A separate two-year extension of that trial confirmed persistent elevations in fasting glucose and HbA1c with continued MK-677 use.

Pregabalin and Weight Gain

Pregabalin causes dose-dependent weight gain. In the pooled analysis from fibromyalgia trials, 9% of patients on pregabalin 450 mg/day gained more than 7% of baseline body weight versus 2% on placebo, per the FDA label. Weight gain with gabapentinoids is thought to involve increased appetite mediated through CNS mechanisms and potentially through effects on lipogenesis. The added body mass can worsen insulin sensitivity, compounding MK-677's direct effect on glucose metabolism.

Monitoring Protocol

For any patient using both agents, the following labs and assessments should be tracked:

| Parameter | Baseline | 4 Weeks | 12 Weeks | Every 6 Months | |---|---|---|---|---| | Fasting glucose | Yes | Yes | Yes | Yes | | HbA1c | Yes | No | Yes | Yes | | IGF-1 | Yes | Yes | Yes | Yes | | Weight / BMI | Yes | Yes | Yes | Yes | | Edema assessment | Yes | Yes | Yes | Yes | | Sedation screening (Epworth) | Yes | Yes | No | No |

If fasting glucose exceeds 100 mg/dL or HbA1c rises above 5.7%, the prescribing clinician should consider reducing MK-677 dose from 25 mg to 10 mg or discontinuing it. An IGF-1 level persistently above the age-adjusted upper limit of normal warrants the same dose reduction.

Dose-Adjustment Strategies

No published dose-adjustment guideline exists for this specific combination because MK-677 remains investigational. The following recommendations are based on each drug's known pharmacology and the general principle of starting low and titrating slowly.

Starting the Combination

If a patient already takes a stable pregabalin dose and plans to add MK-677, begin at 10 mg/day (not the commonly cited 25 mg "full dose"). Assess sedation, weight, and ankle circumference at 2 weeks before increasing. If a patient is starting pregabalin while already on MK-677, begin pregabalin at 75 mg twice daily (the standard initiation dose per the FDA label) and titrate no faster than every 7 days.

When to Reduce or Stop

Reduce or stop MK-677 first if the patient develops:

• Fasting glucose above 126 mg/dL on two separate measurements
• Peripheral edema causing functional impairment (difficulty wearing shoes, skin changes)
• Excessive daytime sedation that persists beyond 2 weeks of combination use

Pregabalin should not be discontinued abruptly. The FDA label recommends tapering over a minimum of one week to avoid withdrawal seizures, insomnia, nausea, and headache. MK-677, by contrast, can be stopped without a taper because it does not produce physical dependence through receptor downregulation in the same way.

Abuse Potential and Regulatory Considerations

Pregabalin is a Schedule V controlled substance under the DEA, reflecting its recognized abuse potential, particularly at supratherapeutic doses where it produces euphoria and dissociative effects. Post-marketing surveillance in Europe led to increased scheduling in several countries. MK-677 is not DEA-scheduled but is prohibited by the World Anti-Doping Agency (WADA) under section S2 (peptide hormones, growth factors, and related substances).

Off-Label and Research Context

MK-677 has never received FDA approval for any indication. Its use is entirely off-label or investigational. Prescribers who recommend this combination assume additional medicolegal responsibility because both agents carry distinct regulatory flags. Clinicians should document the clinical rationale, obtain informed consent covering the investigational status of MK-677, and note that no interaction study between the two drugs has been conducted.

Patient Counseling Points

Patients considering or already using this combination should receive specific, actionable guidance rather than generic warnings.

Driving and Operating Machinery

Both drugs impair alertness. Pregabalin's FDA label carries an explicit warning about driving impairment, and MK-677's sleep-promoting effects can extend into morning hours. Patients should not drive or operate heavy equipment during the first 5-7 days after starting either drug or after any dose increase of either drug.

Alcohol Avoidance

Alcohol magnifies the sedative and edema-producing effects of both agents. Even moderate alcohol intake (two standard drinks) on top of this combination can produce significant next-day cognitive impairment. The pregabalin FDA label recommends avoiding alcohol, and this advice applies doubly when MK-677 is co-administered.

Recognizing Warning Signs

Patients should contact their prescriber if they notice:

• Rapid weight gain exceeding 2 kg in one week (suggests fluid retention)
• Morning blood glucose readings above 126 mg/dL on home monitoring
• Persistent daytime sleepiness that does not improve after the first two weeks
• New or worsening shortness of breath (could indicate heart failure exacerbation)
• Numbness or tingling that worsens (pregabalin side effect that may be confused with neuropathy progression)

What the Evidence Does Not Cover

No randomized controlled trial has tested MK-677 and pregabalin together. The interaction profile described here is constructed from each drug's individual pharmacology, FDA labeling, and clinical trial adverse-event data. This is standard practice for drug combinations where direct interaction studies do not exist, but it means the magnitude of additive risk is estimated, not measured. A 2023 systematic review of MK-677 safety data by Sigalos and Pastuszak noted that most ibutamoren studies enrolled fewer than 100 participants and lasted 12 months or less, limiting long-term safety conclusions.

Clinicians prescribing both agents should report unexpected adverse events to the FDA MedWatch program to build the post-marketing evidence base for this combination.